Your session is about to expire
← Back to Search
Low Titer Whole Blood for Hemorrhagic Shock (TOWAR Trial)
TOWAR Trial Summary
This trial aims to compare the efficacy and safety of low titer whole blood resuscitation to standard care resuscitation for patients at risk of hemorrhagic shock.
TOWAR Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTOWAR Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TOWAR Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Doctors cannot use veins or bones for my treatments.I am at risk of severe bleeding and being taken to a hospital for a blood transfusion.My blood pressure was 90 or lower and my heart rate was 108 or higher.You have only fallen from a standing position and not experienced any other injury mechanism.I have burns without any other injuries.I have an injury that exposed my brain or was caused by a gunshot.I or a family member have expressed concerns about participating in the study.I am between 18 and 90 years old.People who have experienced near-drowning or hanging incidents will not be included.I had a traumatic arrest and received CPR for more than 5 minutes without my vital signs returning.
- Group 1: Whole Blood
- Group 2: Standard Care
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can people who are over 30 years old participate in this research project?
"Eligibility for this study appears to be restricted to those aged 18-89."
Are new patients able to join this clinical trial?
"Correct, the clinicaltrials.gov listing for this study confirms that it is actively recruiting participants. The trial was first posted on 4/19/2022 and was last updated on 9/24/2022. The study is looking for 1020 participants at 2 sites."
Is it dangerous to receive low titer whole blood transfusions?
"While there are Phase 2 trial data supporting the safety of low titer whole blood, there is currently no information regarding its efficacy. As such, our team has given it a score of 2."
Which patients would be a good match for this type of clinical research?
"Patients that wish to enroll in this study must have experienced shock and hemorrhagic, be between 18-89 years old. Currently, the trial is seeking a total of 1020 participants."
How many individuals are included in this research project?
"The most recent information available on clinicaltrials.gov affirms that this study is still looking for patients. This particular trial was first posted on 4/19/2022 and was updated as recently as 9/24/2022. They are hoping to enroll 1020 people at 2 locations."
Share this study with friends
Copy Link
Messenger